吡格列酮与贝沙罗汀联合用于口腔癌化学预防的临床前证据
本研究在口腔癌与白斑细胞系中联合使用PPARγ激动剂吡格列酮和RXRα激活剂贝沙罗汀,发现联合处理可增加PPARγ DNA结合活性与IVL启动子活性,并降低细胞增殖,效果优于单药。作者认为该临床前项目有效,但需更多研究探索其化学预防潜力。
要点
- 正常组织中IVL表达显著高于HNSCC肿瘤组织(p<0.0001)。
- 吡格列酮剂量依赖性增加PPARγ DNA结合活性与IVL启动子活性(p<0.01和p<0.0001)。
- 吡格列酮与贝沙罗汀联合降低细胞增殖,所有联合对比单药至少p<0.05。
核心结论
- 靶向PPARγ/RXRα异二聚体的吡格列酮与贝沙罗汀联合在该临床前项目中有效,且在癌前病变和口腔癌细胞系中均有功能。
- 作者认为更好地理解下游对细胞增殖影响的分子机制可能具有临床意义,但需更多研究探索这些药物在化学预防中的潜力。
研究设计与样本
- 临床前研究,使用口腔癌和白斑细胞系(MSK Leuk1和CA 9-22)处理以PPARγ激动剂吡格列酮和RXRα激活剂贝沙罗汀。
- 采用报告基因试验、基因组数据、MTT试验和western blot分析PPARγ激活、细胞增殖、凋亡活性及表型包括药效标志物外皮蛋白(IVL)。
主要发现
- HNSCC肿瘤与正常组织的微阵列分析显示,正常组织中IVL表达显著高于HNSCC肿瘤(p<0.0001)。
- 在MSK Leuk1和CA 9-22细胞系中,吡格列酮剂量依赖性增加PPARγ DNA结合活性和IVL启动子活性(p<0.01和p<0.0001)。
- 吡格列酮与贝沙罗汀联合处理增加PPARγ DNA结合活性和IVL启动子活性(p<0.01和p<0.0001)。
- MTT分析显示吡格列酮与贝沙罗汀处理降低细胞增殖,所有联合对比单药处理至少p<0.05显著。
- western blot显示联合处理增加IVL蛋白水平。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者指出需更多研究探索这些药物在化学预防中的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) requires new treatments and targeted approaches to improve survival. The peroxisome proliferator-activated receptor γ (PPARγ) and retinoic X receptor alpha (RXRα) nuclear receptor pathways may be targetable with repurposed Food and Drug Administration (FDA)-approved agents for prevention and treatment. METHODS: Oral cancer and leukoplakia cell lines were treated with the PPARγ agonist (pioglitazone) and RXRα activator (bexarotene). PPARγ activation, cellular proliferation, apoptosis activity and phenotype, including the pharmacodynamic marker, involucrin (IVL), were subsequently analyzed using a reporter gene assay, genomic data, MTT assay and western blot. RESULTS: Microarray analysis of HNSCC tumor versus normal tissue shows IVL expression is significantly increased in normal tissue compared to HNSCC tumors (p < 0.0001). In MSK Leuk1 and CA 9-22 cell lines, pioglitazone increases PPARγ DNA binding activity and IVL promoter activity in a dose dependent manner (p < 0.01 and p < 0.0001). Combination treatment with pioglitazone and bexarotene increases PPARγ DNA binding activity and IVL promoter activity (p < 0.01 and p < 0.0001). MTT analysis shows decreases in cell proliferation when cells are treated with pioglitazone and bexarotene. Decreases in cell proliferation are significant to at least p < 0.05 for all combination versus single agent treatments. Western blot on whole-cell lysate from cells treated with pioglitazone and bexarotene alone or in combination for IVL showed increased protein levels with combination treatment. CONCLUSIONS: Targeting the PPARγ/RXRα heterodimer with pioglitazone and bexarotene was effective in this preclinical project. This was functional in both preneoplastic and oral cancer cell lines. A better understanding of the molecular mechanism on downstream effects on cellular proliferation could potentially have implications clinically, both in oral preneoplasia and possibly head and neck cancer; however, more research needs to be done to explore the potential these medications have in chemoprevention.
引用
- Rosas RR, Nachbor KM, Handley N, et al. Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention. Head Neck. 2021. PMID: 34931381. doi:10.1002/hed.26959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。